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Abstract
Background: Targeting Signal Transducer and Activator of Transcription 3 (STAT3) signaling is an attractive
therapeutic approach for most types of human cancers with constitutively activated STAT3. A novel small
molecular STAT3 inhibitor, FLLL32 was specifically designed from dietary agent, curcumin to inhibit constitutive
STAT3 signaling in multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells.
Results: FLLL32 was found to be a potent inhibitor of STAT3 phosphorylation, STAT3 DNA binding activity, and the
expression of STAT3 downstream target genes in vitro, leading to the inhibition of cell proliferation as well as the
induction of Caspase-3 and PARP cleavages in human multiple myeloma, glioblastoma, liver cancer, and colorectal
cancer cell lines. However, FLLL32 exhibited little inhibition on some tyrosine kinases containing SH2 or both SH2
and SH3 domains, and other protein and lipid kinases using a kinase profile assay. FLLL32 was also more potent
than four previously reported JAK2 and STAT3 inhibitors as well as curcumin to inhibit cell viability in these cancer
cells. Furthermore, FLLL32 selectively inhibited the induction of STAT3 phosphorylation by Interleukin-6 but not
STAT1 phosphorylation by IFN-g.
Conclusion: Our findings indicate that FLLL32 exhibits potent inhibitory activity to STAT3 and has potential for
targeting multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells expressing constitutive STAT3
signaling.
Introduction
The Signal Transducer and Activator of Transcription 3
(STAT3) protein is a member of the STAT family of
transcription factors which are initially located in the
cytoplasm in their inactive form. After stimulation by
extracellular signals, such as cytokines, growth factors
and hormones, Janus kinases (JAKs) are activated and
then induce the phophorylatation of STAT3 at tyrosine
residue 705 (Y705) [1]. Phosphorylated STAT3 proteins
dimerize via their Src-homology 2 (SH2) domains, and
translocate to the nucleus where they regulate the
expression of numerous critical genes involved in cell
cycle progression, proliferation, migration and invasion,
and survival [1]. However, the constitutive activation of
STAT3 is frequently detected in clinical samples from a
wide range of human carcinoma and established human
cancer cell lines, such as multiple myeloma, glioblas-
toma, colorectal and hepatocellular carcinoma [1-5].
Importantly, elevated levels of STAT3 phosphorylation
were correlated with the tumor invasion, metastasis, and
worse prognosis in colorectal, hepatocellular and other
carcinoma [2-5].
Blocking constitutive STAT3 signaling in carcinoma
cells by STAT3 antisense oligonucleotides, STAT3 small
interfering RNAs (siRNAs), or stable transfection of
dominant-negative STAT3 [5] can inhibit cancer cells
growth, invasion and metastasis, and induce apoptosis.
Furthermore, inhibition of constitutive STAT3 signaling
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growth, and decreased the invasion of human hepatocel-
lular carcinoma cells, and also induced apoptosis in
multiple myeloma cells [7]. These findings suggest that
constitutive STAT3 signaling is crucial to the survival,
invasion, and growth of human carcinoma cells. Target-
ing the STAT3 pathway directly should be a promising
and novel form of treatment for these human cancers.
A few non-peptide STAT3 SH2 inhibitors were recently
developed to inhibit STAT3 dimerization, including
Stattic [8], STA-21 [9], and S3I-201 [10]. Several new
inhibitors of JAK2, the upstream kinase of STAT3, such
as AG490 [6], WP1066 [11] have also been reported.
We have recently developed a series of novel curcu-
min-derived small molecule inhibitors of the JAK2/
STAT3 pathway. Curcumin is the primary bioactive
compound isolated from turmeric, the dietary spice
made from the rhizome of Curcuma longa. Curcumin is
known to inhibit several targets closely associated with
cancer cell proliferation, in particular JAK2/STAT3
pathway [12,13]. Because of its poor bioavailability and
potency, curcumin has somewhat limited potential as an
anti-cancer drug. However, we utilized curcumin as a
lead compound to design new small molecule STAT3
inhibitors. One compound identified by our group,
named as FLLL32, has been shown to selectively inhibit
STAT3 phosphorylation, STAT3 DNA binding activities,
cell viability, and induce apoptosis in multiple myeloma,
glioblastoma, colorectal and hepatocellular carcinoma
cancer cells with constitutively activated STAT3
signaling.
Results
FLLL32, a curcumin analog that is specifically designed to
target STAT3
Computer models with molecular docking showed that
only the keto form of curcumin binds to the STAT3
SH2 dimerization site (Table 1). However, curcumin
exists almost entirely in the enol form in solution.
FLLL32 is a diketone analogue of curcumin (Figure 1).
FLLL32 was designed to lock its derivatives exclusively
into the diketo form via substituting the two hydrogens
on the middle carbon with spiro-cyloalkyl rings. Mole-
cular docking showed that FLLL32 has better binding
potencies to the STAT3 SH2 binding site (FLLL32 is
25-fold stronger in STAT3 SH2 binding) than the keto
tautomer of curcumin (Table 1).
The STAT3 inhibitor, FLLL32 down-regulated STAT3
phosphorylation in cancer cells
W ef i r s te x a m i n e dw h e t h e rFLLL32 inhibits STAT3
phosphorylation at Tyrosine residue 705 (Y705). Phos-
phorylation of STAT3 at residue Y705 plays an impor-
tant role in its activity and nuclear translocation. We
detected the effects of FLLL32 on STAT3 phosphoryla-
tion by Western blots with a phospho-Y705-specific
STAT3 antibody in a panel of glioblastoma, multiple
myeloma, colorectal and liver cancer cell lines known to
express high endogenous levels of constitutively acti-
vated STAT3. We found FLLL32 effectively decreased
the levels of phosphorylated STAT3 (P-STAT3, Y705)
in SW480 (Figure 2A) and HCT116 (Figure 2B) colorec-
tal cancer cells and curcumin is not as potent as
FLLL32. STAT3 is phosphorylated at tyrosine residue
(Y705) and activated by upstream kinases such as Janus
kinase 2 (JAK2) [14,15]. So we examined the phosphor-
ylation of JAK2 (Y1007/1008) in these two colon cancer
cell lines. We found that FLLL32 also inhibits JAK2
phosphorylation in both cell lines. FLLL32 with higher
concentration (10 μM) also inhibited the phosphoryla-
tion of STAT3 at residue Ser727 in SW480 cancer cell
line but in HCT116 cancer cell line, the phosphoryla-
tion of STAT3 (Ser 727) could not be detected
Table 1 Docking energies of curcumin and FLLL32 to
STAT3
Docking free energy (kcal/mol) to STAT3
Curcumin -8.1(keto)
no binding (enol)
FLLL32 -8.5
Curcumin has both enol and keto form. FLLL32 had better binding potency
than curcumin.
FLLL32
Curcumin
(diketone form)
Figure 1 The structures of FLLL32 and curcumin.T h ec h e m i c a l
modifications made to FLLL32 prevent enolization and are
proposed to confer greater stability and better access to critical
domains in STAT3.
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Page 2 of 10(Figure 2A, 2B). The phosphorylation ERK1/2 was
not inhibited by FLLL32 in both colon cancer cell lines
(Figure 2A, B).
We next examined the effects of FLLL32 in U87 and
U251 glioblastoma cells (Figure 2C and Additional File
1A). FLLL32 with higher concentration (10 μM) inhib-
ited the phosphorylation of STAT3 at residue Ser727 in
U251 glioblastoam cell line (Additional File 1A), but in
U87 glioblastoama cell line the STAT3 Ser 727 phos-
phorylation could not be detected (Figure 2C). The
phosphorylation ERK1/2 was not reduced by FLLL32
(Figure 2C and Additional File 1A). FLLL32 was also
more potent than curcumin to inhibit STAT3 Y705 and
JAK2 phosphorylation in U266 (Figure 2D) and ARH-77
(Additional File 1B) multiple myeloma cell lines. Higher
concentration (5 μM) of FLLL32 also slightly inhibited
the phosphorylation of STAT3 at residue Ser727 in both
multiple myeloma cell lines.
The effects of STAT3 phosphorylation in liver cancer
cells were also examined. FLLL32 inhibit STAT3 Y705
phosphorylation in SNU449 (Figure 2E), HEP3B (Figure
2F), SNU387 (Additional File 1C), and SNU398 (Addi-
tional File 1D) liver cancer cells. However, the phos-
phorylation of ERK1/2 was not reduced except in
SNU387 cells. The phosphorylation of mTOR was also
not reduced in HEP3B and SNU398 cells. FLLL32 has
little effect in inhibiting STAT3 S727 phosphorylation in
SNU449, HEP3B, SNU398 and liver cancer cells lines
B                                            D                   F                   
A                                             C                  E                   
Figure 2 FLLL32 inhibited STAT3 phosphorylation, and induced apoptosis in (A) SW480, (B) HCT-116 colorectal, (C) U87 glioblastoma,
(D) U266 multiple myeloma, and (E) SNU449, (F) HEP3B liver cancer cells. Cells were treated with FLLL32 (2.5-10 μM) or curcumin (5-10
μM) of for 24 hours. Decreases in P-STAT3 by FLLL32 were associated with decreased STAT3 downstream target genes and increased cleavage of
caspase-3 and PARP. The phosphorylation of ERK1/2 and/or mTOR was not obviously reduced.
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Page 3 of 10(Figure 2E, F, Additional File 1D). We were not able to
detect JAK2 phosphorylation in these liver cancer cell
lines and in SNU387 cell line, the phosphorylation of
STAT3 (Ser727) could not be detected.
FLLL32 inhibits the expression of the STAT3 downstream
targets and induced apoptosis in cancer cells
FLLL32 was also found to down-regulate the expression
of STAT3 downstream targets that are involved in cell
proliferation, survival, and other functions. Not all of
the cancer cell lines expressed the same STAT3 down-
stream targets but cyclin D1, Bcl-2, survivin, DNMT1
and TWIST1 were among the most common STAT3
downstream targets expressed and were inhibited by the
STAT3 inhibitor, FLLL32 (Figure 2 and Additional File
1).
With the decreases of STAT3 phosphorylation and
STAT3 downstream targets, the induction of apoptosis
by FLLL32 was as evidenced by cleaved poly-ADP ribose
polymerase (PARP) PARP and caspase-3 in these human
cancer cell lines (Figure 2 and Additional File 1).
FLLL32 is also more potent than curcumin to induce
apoptosis in these cancer cells. We also tested a pre-
viously reported STAT3 inhibitor Stattic [11] and a pre-
viously reported JAK2 inhibitor WP1066 [11] as positive
controls to detect their effects on apoptosis. Stattic and
WP1066 were also found to inhibit STAT3 phosphoryla-
tion and induce apoptosis indicated by the cleaveage of
capase-3 in HCT116 colon cancer cells (Figure 3A) and
U266 multiple myeloma cells (Figure 3B).
FLLL32 inhibited STAT3 phosphorylation induced by IL-6
but not STAT1 phosphorylation induced by IFN-g
Some of the cancer cells or cell lines employed in these
studies do not express constitutively phosphorylated
STAT3, such as the MDA-MB-453 breast cancer cell
line. IL-6 is a cytokine which can induce the phosphory-
lation of STAT3 (Y705) [16-18]. We hypothesized that
FLLL32 would be potent enough to inhibit IL-6 induced
STAT3 phosphorylation. We found that pretreatment
with FLLL32 but not curcumin (20 μM) was able to
inhibit the induction of STAT3 phosphorylation by IL-6
in MDA-MB-453 breast cancer cells, and the effect of
FLLL32 was more potent than curcumin (Figure 4A, B).
However, pre-treatment of cells with FLLL32 had no
impact on the phosphorylation of STAT1 induced by
IFN-g (Figure 4C). These results indicate the selectivity
of FLLL32 on STAT3 but not STAT1.
FLLL32 inhibited STAT3 DNA binding activity
After activation by phosphorylation at residue Y705,
STAT3 dimerizes and translocates to the nucleus and
induces the expression of downstream genes by bind-
ing specific DNA-response elements. We next
examined the effect of FLLL32 on STAT3 DNA bind-
ing activity in U87 glioblastoma, U266 multiple mye-
loma and SW480 colorectal cancer cells. After 24
hours of treatment with FLLL32, the levels of STAT3
DNA-binding activity were decreased significantly in
SW480, U87, and U266 cells (Figure 5A-C), and simi-
larly the inhibitory effect of FLLL32 is more potent
than curcumin (Figure 5A-C).
Effects of FLLL32 on human protein and lipid kinases
We further examined whether FLLL32 inhibits other
human kinase activity using a kinase profile assay.
FLLL32 exhibited almost no inhibition (IC50 are greater
than 100 μM) on tyrosine kinases containing SH2 or
both SH2 and SH3 domains, such as JAK3, Lck, Syk,
ZAP-70, TYK2, Abl-1, BTK, Lyn and Yes (Table 2).
FLLL32 also exhibited little inhibition (IC50 are as high
as 57.33 μMt o1 0 0μM) on other protein kinases such
as AKT1, CDK4/Cyclin D1, FAK, JNK1-a,m T O R ,P I 3 K
(P110a/85a,P 1 1 0 b/85a), PKA, PKCa,P K C g (Table 2).
As one of the positive controls, a known PI3K inhibitor,
LY294002, the IC50 is 0.7853 μM. Several protein
kinases (AKT, FAK and PKA) that were known to be
inhibited by curcumin [19] were not inhibited by
FLLL32 (Table 2). These results also support the specifi-
city of FLLL32 to inhibit STAT3.
The inhibitory efficacy of FLLL32 compared to other JAK2
and STAT3 inhibitors
Finally, the growth inhibitory activities of FLL32 were
compared with those previously reported inhibitors in a
panel of colorectal, glioblastoma, multiple myeloma and
liver cancer cells lines. MTT assays were used to gener-
ate dose-response curves and evaluate cell viability fol-
lowing 72 hours of treatment with different
concentrations of JAK2/STAT3 inhibitors, including
FLLL32, WP1066, AG490, Stattic, S3I-201, and curcu-
min. The IC50 values of each compound in each cell
line were calculated and listed in Table 3. In our testing,
FLLL32 was more potent than other compounds in the
growth suppression of each cell lines tested.
FLLL32 suppresses tumor growth in vivo
To determine the effect of FLLL32 to suppress tumor
growth, mouse xenograft experiments were then per-
formed to in an in vivo system. Two groups of 16
NON/SCID mice were obtained for tumor xenografts
with the MDA-MB-231 breast cancer cell line. FLLL32
also could inhibit STAT3 phosphorylation and induce
apoptosis in MDA-MB-231 breast cancer cells (Addi-
tional File 2A). After seeding and allowing the tumors
to develop for 7 days, seven mice from each group were
given daily intraperitoneal doses of 50 mg/kg FLLL32
whereas the other nine were given DMSO vehicle to
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resulted in significantly reduced tumor burdens in the
MDA-MB-231 xenografts in mice compared to their
DMSO-treated mice (Additional File 2B). These results
indicated that FLLL32 not only potent in suppressing
cancer cell growth in vitro b u ta l s op o t e n ti ns u p p r e s -
sing tumor grow in mice in vivo.
Discussion
Colorectal cancer is the third most common form of can-
cer and the second most common cause of cancer-related
death in the United States. Despite advances in the treat-
ment of colorectal cancer, the five-year survival rate has
only increased to 65%. Hence, novel therapeutic
approaches of more effective treatments are much needed
for colorectal cancer. The constitutive activation of
STAT3 is frequently detected in primary human colorectal
carcinoma cells and established human colorectal cancer
cell lines [2,3,20,21] and elevated levels of STAT3 phos-
phorylation have been correlated with tumor invasion,
nodal metastasis, and staging (P < 0.05) [3,20]. Addition-
ally, constitutive STAT3 activation in colorectal cancer
cells is associated with invasion, survival, and growth of
colorectal cancer cells and the colorectal tumor model in
mice in vivo [2,21-23]. These reports indicate that STAT3
is one of the major oncogenic pathways activated in color-
ectal cancer and can serve as a promising therapeutic tar-
get for colorectal carcinoma. Our data in this report
demonstrated that, FLLL32, a novel STAT3 inhibitor, effi-
ciently inhibited STAT3 phosphorylation, STAT3 DNA
binding activity, which resulted the induction of apoptosis
in human colorectal cancer cell lines.
A
B
Figure 3 Stattic (reported STAT3 inhibitor) and WP1066 (reported JAK2 inhibitor) were able to inhibit STAT3 phosphorylation and
induce apoptosis indicated by increased cleaveage of capase-3 in (A) HCT116 colon cancer and (B) U266 multiple myeloma cells.
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Figure 4 Pre-treatment of cells with FLLL32 effectively inhibited the stimulation of STAT3 phosphorylation induced by IL-6, but had
little impact on the phosphorylation of STAT1 induced by IFN-g.
A                                                                       B
C
Figure 5 FLLL32 inhibited STAT3 DNA binding activity in (A) SW480 colorectal cancer cells, (B) U87 glioblastoma cells, and (C) U266
multiple myeloma cells (* P < 0.05).
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3 (STAT3) signaling pathway has been implicated in the
proliferation, chemoresistance, and survival of multiple
myeloma cells [4,24]. Multiple myeloma is the second
most common hematologic malignancy and will account
for over 20,000 new diagnoses in 2009 in the United
States. The incidence of the disease is rising and
currently over 80,000 patients are living with multiple
myeloma in the United States. Despite the advent of
novel agents including lenalidomide and bortezomib,
however, the disease remains incurable and new thera-
pies are desperately needed. Our results presented in
here also demonstrated that FLLL32 could efficiently
inhibit STAT3 phosphorylation, STAT3 DNA binding
activity, and induced of apoptosis in human multiple
myeloma cell lines indicating that FLLL32 may be a
potent therapeutic agent for this type of cancer with
STAT3 is constitutively activated.
The third type of cancer we tested with FLLL32 is
glioblastoma. Glioblastoma is the most common and
aggressive of the primary brain tumors and 10,000 cases
of glioblastoma are diagnosed in the United States each
year. Glioblastoma continues to have very poor prog-
nosis despite advances in chemotherapy and radiation
therapy [25,26]. Many clinical cases of glioblastoma and
glioblastoma cell lines express constitutively activated
STAT3 [27,28]. Overexpression of IL-6, an upstream
regulator of STAT3 [29] is also detected in glioblastoma
and is a marker of malignancy [30,31]. The persistent
activation of STAT3 is in part, also attributable to an
autocrine action of IL-6 in the glioblastoma cells [32].
However, STAT3 was reported to play a pro-oncogenic
or tumor-suppressive role depending on the the genetic
background of the tumor [33]. Our results showed that
FLLL32 was a potent inhibitor in inhibiting STAT3
phosphorylation and STAT3 DNA binding activity in
human glioblastoma cell lines. Human glioblastoma cells
were induced to apoptosis by the inhibition of STAT3
with FLLL32.
Furthermore, the inhibitory efficacy of FLLL32 in liver
cancer cells was examined. Liver cancer or hepatocellu-
lar carcinoma is one of the most serious of cancers.
According to the American Cancer Society, the five-year
relative survival rates are currently at 11% for all stages,
7.7% for regional metastasis, and 2.9% for distant metas-
tasis. Hence, there is an urgent need to develop more
effective treatments for liver cancer. Patients with any
stage of liver cancer may appropriately be considered
candidates for clinical trials using new inhibitors
because of the poor response to chemotherapy as con-
ventionally used. The constitutive activation of STAT3
is frequently detected in clinical incidences of liver can-
cer and in more than 50% of human liver cancer cell
lines but not in normal or non-transformed human cells
[5,34,35]. The constitutive activation of STAT3 in liver
cancer is frequently due to the aberrant methylation and
silencing of Suppressor of Cytokine signaling-1 (SOCS-
1) and -3 (SOCS-3) [34,35]. Constitutive STAT3 signal-
ing contributes to liver cancer progression by promoting
angiogenesis, survival, metastasis, and growth of liver
cancer cells [5,34,35]. Again, our data demonstrated that
Table 2 The effect of FLLL32 on human protein and lipid
kinases using a kinase profile assay
Protein
Kinases
IC50
(μM)
Tyrosine kinases contain SH2 Domain JAK3 >100
Lck >100
Syk >100
ZAP-70 >100
TYK2 >100
Tyrosine kinases containSH2 and SH3
Domains
Abl-1 >100
BTK >100
Lyn >100
Yes >100
Other human protein or lipid kinases AKT1 >100
CDK4/CyclinD1 >100
FAK >100
JNK1-a1 >100
MEK1 >100
mTOR >100
PI3K (P110a/
85a)
63.23
PI3K (P110b/
85a)
57.33
PKA >100
PKCa >100
PKC-g >100
Table 3 IC50 values (μM) of FLLL32, curcumin, and other
JAK2/STAT3 or STAT3 SH2 inhibitors in human colorectal
cancer cells (C), glioblastoma cells (G), multiple myeloma
(MM) and liver (L) cancer cells
FLLL32 WP1066 Stattic S3I-201 AG490 Curcumin
SW480 (C) 0.38 1.98 0.43 >100 86.8 10.26
HCT-116 (C) 0.32 1.51 0.96 >100 50.5 10.91
U87 (G) 0.19 5.78 0.73 55.10 >100 6.91
U251 (G) 0.26 5.04 0.84 97.30 50.70 7.10
U266 (MM) 0.48 1.38 0.99 8.87 9.50 4.76
ARH77 (MM) 2.34 3.43 2.57 35.25 28.20 10.13
SNU-449 (L) 2.04 3.85 2.50 >100 >100 9.88
SNU-398 (L) 0.65 4.88 3.23 16.20 24.30 5.37
Hep3B (L) 2.31 10.20 17.78 >100 >100 68.12
SNU-387 (L) 2.89 5.17 4.30 >100 >100 25.54
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and induced apoptosis in four independent human liver
cancer cell lines. These results indicate that FLLL32 also
has potential as a therapeutic agent for liver cancer cells
expressing persistently activated STAT3.
In addition, FLLL32 also potent to inhibit STAT3
phosphorylation and induce apoptosis in MDA-MB-231
breast cancer cells. The potency of FLLL32 was further
confirmed in MDA-MB-231 breast cancer xenografts in
mouse model in vivo.T h e r e f o r e ,F L L L 3 2i sn o to n l y
potent in cancer cells in vitro but also in tumor cells in
animal model in vivo and may have future potential to
target tumor cells that express persistently activated
STAT3 in cancer patients.
Curcumin has been demonstrated as a dietary agent
that can inhibit STAT3[16,17]. FLLL32 was designed as
a new analog which specifically targets STAT3 with
higher binding potency and selectivity. Our data demon-
strated that FLLL32 was more potent than curcumin to
inhibit STAT3 phosphorylation and STAT3 DNA bind-
ing activity, downregulate STAT3 target genes, and
induce cancer cells apoptosis. However, the phosphory-
lation of mTOR and ERK was not obviously reduced by
FLLL32. FLLL32 also has little effect on STAT1 phos-
phorylation stimulated with IFN-g. In addition, FLLL32
exhibited little inhibition on some of the tyrosine
kinases containing SH2 or both SH2 and SH3 domains,
and other protein kinases by using kinase profile assay.
These results further support the specificity of FLLL32
to inhibit STAT3.
After activated by some cell surface cytokines, such as
IL-6, IFN-g, JAK2 phosphorylates and activates cytoplas-
mic STAT3 protein to an active dimer, which translo-
cates to the nucleus and induce the transcription of
specific target genes [14,15]. We found that FLLL32
inhibited P-JAK2 (Y1007/1008) in some of the cancer
cell lines, which may explain the inhibition of the
STAT3 phosphorylation in those cancer cell lines. Sev-
eral new inhibitors of JAK2/STAT3 pathway were
recently reported, such as Stattic [8], STA-21 [9], S3I-
201 [10], AG490 [6], WP1066 [11]. Here, Stattic and
WP1066 were used as positive control to detect their
effects on apoptosis in HCT116 colon cancer and U266
multiple myeloma cells, which conformed the JAK2/
STAT3 pathway may be an important target to induce
the apoptosis of cancer cells. Furthermore, FLLL32 was
found to be potent than other reported JAK2/STAT3
inhibitors, including FLLL32, WP1066, AG490, Stattic,
S3I-201, and curcumin in our cancer cell lines.
Conculsions
Our results have demonstrated that FLLL32 is an effec-
tive STAT3 inhibitor to inhibit STAT3 phophorlation,
STAT3 DNA binding activity, STAT3 downstream tar-
get gene expression and induce apoptosis in human can-
cer cells from four independent cancer types such as
multiple myeloma, glioblastoma, colorectal and liver
cancers. FLLL32 was more potent than curcumin and
other reported JAK2/STAT3 inhibitors in the inhibition
of cancer cell viability in our comparisons. Our results
suggest that FLLL32 is a potent therapeutic agent for
multiple types of cancer cells expressing constitutive
STAT3 signaling including multiple myeloma, glioblas-
toma, colorectal and liver cancer cells.
Methods
Cell Culture
Human colonrectal cancer cell lines (SW480, HCT116),
glioblastoma cell line (U87, U251), human hepatic can-
cer cell lines (SNU-449, SNU-398, HEP3B and
SNU387), human multiple myeloma cell line (U266 and
ARH-77) and human breast cancer cell lines (MDA-
MB-453, MDA-MB-231) were purchased from the
American Type Culture Collection (Manassass, VA).
These cancer cell lines were cultured in DMEM or
RPMI-1640 supplemented with 10% fetal bovine serum.
Inhibitors
FLLL32, a curcumin-derived STAT3 inhibitor, and
WP1066 [11], a Janus-like kinase 2 (JAK2) inhibitor,
were synthesized in Dr. Pui-Kai Li’s laboratory (College
of Pharmacy, The Ohio State University). STAT3 SH2
inhibitors Stattic [8] and S3I-201 [10], JAK2 inhibitor
AG490 [6] was purchased from Calbiochem (San Diego,
CA). Curcumin was purchased from Sigma-Aldrich Che-
mical Co. (Milwaukee, WI).
Western blot analysis
FLLL32 and curcumin were dissolved in DMSO. Cancer
cells were treated with the listed concentrations of these
agents or DMSO for 24 hours, then lysed in cold RIPA
lysis buffer containing protease inhibitors and subjected
to SDS-PAGE. The primary antibodies were purchased
from Cell Signaling Technologies (Danvers, MA, USA),
including phospho-specific STAT3 (Tyrosine 705), phos-
pho-specific STAT3 (Serine 727), phospho-specific JAK2
(Tyrosine1007/1008), phospho-specific STAT1 (Tyrosine
701), phospho-specific ERK1/2 (Threonine 202/Tyrosine
204), phospho-specific mTOR (Serine 2448), cleaved
Poly (ADP-ribose) polymerase (PARP), cleaved caspase-
3, cyclin D, Bcl-2, survivin, TWIST1 and GAPDH.
DNMT1 primary antibodies were purchased from
abcam Inc (Washington, DC). Membranes were ana-
lyzed with enhanced chemiluminescence Plus reagents
(GE Healthcare) and scanned with a Storm PhosphorI-
mager (Amersham Pharmacia Biotech Inc.).
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The possible effects of FLLL32 on ten purified human
protein kinases were performed at Reaction Biology
Corp. (Malvern, PA) using Kinase profiler assay. The
IC50 inhibitory values of FLLL32 on the kinase activity
were determined using 10 different concentrations of
FLLL32 with 100 μM as the highest concentration.
IL-6 induction of STAT3 phosphorylation
MDA-MB-453 breast cancer cells were seeded and
serum starved overnight. The cells were then left
untreated or were treated with FLLL32 (20 μM), curcu-
min (20 μM) or DMSO for indicated hours. After stimu-
lation with IL-6 (50 ng/mL, Sigma) or IFN-g (50 ng/mL,
Sigma) for 30 min, the cells were harvested and ana-
lyzed by western blot.
STAT3 DNA-binding assays
After treatment with FLLL32, curcumin, or DMSO for
24 hours, the nuclear extract kit (Clontech Inc., Moun-
tain View, CA) was used to prepare cell nuclear extracts
following the manufacturer’s protocol. Nuclear extracts
were analyzed for STAT3 DNA binding activity using
the TransFactor Universal STAT3-specific kits (Clon-
tech Inc., Mountain View, CA) with an ELISA-based
method.
MTT cell viability assay
Cells were seeded in 96-well plates (3,000 cells/well) in
triplicate, and treated with FLLL32 (0.1-10 μmol/L), cur-
cumin (0.5-100 μmol/L), WP1066 (0.5-30 μmol/L), Stat-
tic (0.5-30 μmol/L), S3I-201 (1-100 μmol/L), or AG490
(1-100 μmol/L) for 72 hours. Twenty-five μlo f3 - ( 4 , 5 -
Dimethylthiazolyl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma) was added to each sample and incubated
for 3.5 hours. After this, 100 μl of N, N-dimethylforma-
mide (Sigma) solubilization solution was added to each
well. The absorbance at 595 nm was read the following
day. Half-Maximal inhibitory concentrations (IC50)w e r e
determined using Sigma Plot 9.0 software (Systat Soft-
ware Inc., San Jose, CA).
Mouse xenografts
All animal studies were conducted in accordance with
the standard procedures approved by IACUC at the
Research Institute at nationwide children’sh o s p i t a l .
MDA-MB-231 breast cancer cells (5 × 10
6 in Matrigel)
were implanted subcutaneously into the flank region of
4-6-week-old female NOD/SCID mice. After tumors
developed (7 days), the mice were randomized into two
groups and treated with 50 mg/kg FLLL32 (7 mice) or
DMSO (9 mice) intraperitoneally daily for 18 days.
Tumor growth was determined by measuring the major
(L) and minor (W) diameter with a caliper. The tumor
volume was calculated according to the formula: Tumor
volume = 0.5236 × L × W
2.
Additional material
Additional file 1: FLLL32 inhibited STAT3 phosphorylation in (A)
U251 glioblastoma cells lines. (B) ARH-77 multiple myeloma, (C)
SNU387 and (D) SNU398 liver cancer cells. FLLL32 also inhibited the
expression of Cyclin D1 and/or Bcl-2, DNMT1 and increased the
cleavages of caspase-3 and PARP.
Additional file 2: The effect of FLLL32 on tumor growth in vivo.( A )
FLLL32 inhibited STAT3 phosphorylation and induced apoptosis in MDA-
MB-231 breast cancer cells lines; (B) FLLL32 suppressed the growth of
MDA-MB-231 xenograft tumors in NOD/SCID mice.
Abbreviations
DMEM: Dulbecco’s Modified Eagle Medium; DMSO: Dimethyl sulfoxide;
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; MTT: 3-(4,5-
Dimethylthiazolyl)-2,5-diphenyltetrazolium bromide; PARP: Poly ADP ribose
polymerase; STAT: Signal Transducer and Activator of Transcription; Tyr705:
Tyrosine 705.
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